Optimising bone health in survivors of breast cancer

Lancet Oncology

Volumn 8, Issue 2, 2007, Pages 89-91

  Bundred, Nigel J ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; ESTROGEN; EXEMESTANE; GONADORELIN AGONIST; HORMONE RECEPTOR; LETROZOLE; TAMOXIFEN; ZOLEDRONIC ACID;

BONE DENSITY; BONE DISEASE; BONE MINERAL; BREAST CANCER; CANCER SURVIVOR; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN ACTIVITY; EVIDENCE BASED MEDICINE; FRAGILITY FRACTURE; GYNECOLOGIC DISEASE; HUMAN; LETTER; OSSIFICATION; OSTEOPENIA; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT MONITORING; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; THROMBOEMBOLISM; VERTEBRA FRACTURE;

ANDROSTADIENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; BONE DENSITY; BONE NEOPLASMS; BONE REMODELING; BREAST NEOPLASMS; FEMALE; HUMANS; POSTMENOPAUSE; SURVIVORS; TAMOXIFEN;

EID: 33846465901     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(07)70007-4     Document Type: Letter

References (10)

1. Howell A., Cuzick J., Baum M., et al., ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
2. Coleman R., Banks L., Girgis S., et al., on behalf of the Intergroup Exemestane Study (IES) group. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 8 (2007) 119-127
3. Cummings S., Browner W., Bauer D., et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med 339 (1998) 767-768
4. Lester J., and Coleman R. Bone loss and the aromatase inhibitors. Br J Cancer 93 suppl 1 (2005) 16-22
5. Eastell R., Hannon R., Cuzick J., et al., on behalf of the ATAC Trialists' group. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) Trial (18233230). J Bone Miner Res 21 (2006) 1215-1223
6. Gnant M., Mlineritsch B., Luschin-Ebengreuth G., et al. Zoledronic acid effectively prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol (2007). published online Dec 11, 2006. DOI:10.1200/JCO.2005.02.7102
7. Hillner B., Ingle J., Chlebowski R., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21 (2003) 4042-4057
8. Sambrook P., and Cooper C. Osteoporosis. Lancet 367 (2006) 2010-2018
9. Lester J., Dodwell D., Horsman J., et al. Current management of treatment-induced bone loss in women with breast cancer treated in the United Kingdom. Br J Cancer 94 (2006) 30-35
10. Brufsky A., Harker W., Beck J., et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol (2007). published online Dec 11, 2006. DOI:10.1200/JCO.2005.05.3744